The IC3 Liver Health Study is now recruiting patients across Australia for valuable research to improve liver screening by general practitioners (GPs) in practice.
Rates of liver cancer are steadily increasing both globally and within Australia and, on many occasions, it is being caught too late. There is currently no screening tool for GPs to use in practice to identify hepatocellular carcinoma (HCC), the most common type of liver cancer. The IC3 Trial, supported by the Primary Care Collaborative Cancer Clinical Trials (PC4) group, is seeking to determine the effectiveness of a liver-screening tool to be used by GPs in practice.
Recruitment for this study commenced in July 2022, with the aim of recruiting 2800 participants from diverse population groups through 28 general practices across the country. Unlike the majority of clinical trials, at least one-third of these practices will be located in regional or rural locations where patients are at an increased risk of liver disease.
For more information, please contact the IC3 National Manager, Deborah de Guingand: [email protected] or visit our website: pc4tg.com.au/ic3-trial.